Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Ganglioneuroblastoma: early-phase trial registry

2 of 9 indexed Ganglioneuroblastoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Ganglioneuroblastoma: 9 US clinical trials tracked, 2 recruiting.

Ganglioneuroblastoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 4 of these trials.

Enrollment posture brief

Registry condition ganglioneuroblastoma

OPEN 2 | RECR 22% | LATE 2 | EARLY 5 | RANK #1916 | SPON 4

Nearest open-share peer: Acne (22% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Ganglioneuroblastoma (this)22%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Ganglioneuroblastoma

Ganglioneuroblastoma lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ganglioneuroblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ganglioneuroblastoma is recruiting below its size-band peers.

    2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Ganglioneuroblastoma research.

    Children's Oncology Group accounts for 4 of 9 trials (44.4%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Ganglioneuroblastoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 73 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. Ganglioneuroblastoma research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22Phase 32

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 750 participants

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

NCT03126916

RECRUITING NA 30 participants

Phase II Study of Proton Radiation Therapy for Neuroblastoma

Massachusetts General Hospital

NCT02112617

ACTIVE NOT RECRUITING 10,000 participants

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Children's Oncology Group

NCT00904241

ACTIVE NOT RECRUITING Phase 3 621 participants

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Children's Oncology Group

NCT02176967

ACTIVE NOT RECRUITING Phase 1 65 participants

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Seattle Children's Hospital

NCT02311621

ACTIVE NOT RECRUITING Phase 2 42 participants

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

NCT03786783

ACTIVE NOT RECRUITING Early Phase 1 20 participants

An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors

Mayo Clinic

NCT04040088

COMPLETED Phase 1 99 participants

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Children's Oncology Group

NCT01175356

COMPLETED Phase 2 73 participants

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

NCT01767194

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 2

Named interventions

Most-linked intervention names on Ganglioneuroblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Autologous Hematopoietic Stem Cell Transplantation Procedure
3 trials
Carboplatin Drug
3 trials
Laboratory Biomarker Analysis Other
2 trials
Busulfan Drug
2 trials
Cisplatin Drug
2 trials
Cyclophosphamide Drug
2 trials
Gallium Ga 68-DOTATATE Drug
1 trials
Dexrazoxane Drug
1 trials

US sites by state

Facility locations filed on Ganglioneuroblastoma trials. A trial with sites in several states counts in each.

California 6 trials
Arizona 5 trials
Arkansas 4 trials
Alabama 4 trials
Massachusetts 3 trials
Connecticut 3 trials
Colorado 3 trials
Pennsylvania 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ganglioneuroblastoma page

9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ganglioneuroblastoma condition card totals 9 registered trials; most-linked intervention Autologous Hematopoietic Stem Cell Transplantation; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.